pyrexia

Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

Related to pyrexia: Pyrexia of unknown origin

py·rex·i·a

(pī-rĕk′sē-ə)

Fever.

[New Latin, from Greek purexis, from puressein, to have a fever, from puretos, fever; see pyretic.]

py·rex′i·al, py·rex′ic adj.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

pyrexia

(paɪˈrɛksɪə)

(Pathology) a technical name for fever

[C18: from New Latin, from Greek purexis, from puressein to be feverish, from pur fire]

pyˈrexial, pyˈrexic adj

Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

fe•ver

(ˈfi vər)

n.

1. an abnormally high body temperature.

2. any of various diseases in which high temperature is a prominent symptom, as scarlet fever or rheumatic fever.

3. intense nervous excitement: in a fever of anticipation.

v.t.

4. to affect with or as if with fever.

v.i.

5. to become feverish; have or get a fever.

[before 1000; Middle English; Old English fefer < Latin febris fever]

ThesaurusAntonymsRelated WordsSynonymsLegend:

Switch to new thesaurus

Noun

pyrexia - a rise in the temperature of the body; frequently a symptom of infection

febricity, febrility, fever, feverishness

symptom - (medicine) any sensation or change in bodily function that is experienced by a patient and is associated with a particular disease

hyperpyrexia - extremely high fever (especially in children)

Translations

piressia

py·rex·i·a

n. pirexia, condición febril.

English-Spanish Medical Dictionary © Farlex 2012

Mentioned in ?

References in periodicals archive ?

Table 1: The portrayal of clinical markers of bovine tropical theileriosis of 21 calves Clinical markers Recorded Number of calves percentage (%) revealed Lymph nodes enlargement 100 21/21 Pallor MM 90.48 19/21 Reduced appetite 90.48 19/21 Pyrexia (40-42[degrees]C) 85.71 18/21 Pica 66.67 14/21 Coughing and respiratory 66.67 14/21 distress Lacrimation 66.67 14/21 Exophthalmia 52.38 11/21 Petechiae and/or ecchymoses 47.62 10/21 Lateral Recumbency 38.10 08/21 Submandibular or Ventral 38.10 08/21 edema Diarrhea 14.29 03/21 Melena 9.52 02/21 Haemoglobinuria 9.52 02/21 Jaundice (yellow) MM 9.52 02/21

Evaluation of clinical markers for diagnosis of bovine theileriosis--a study of 21 calves

AEs occurring in three or more patients included abdominal pain, headache, nasopharyngitis, pyrexia, and vomiting.

Alnylam says data shows lumasiran demonstrated reductions in urinary oxalate

The clinical signs disappeared and pyrexia was controlled in all the animals within 3 days of treatment (Sumathi and Veena, 2012).Blood smear examination after 4th day blood smear examination revealed complete absence of piroplasm in erythrocytes.

Therapeutic management of bovine theileriosis--a report of 13 cattle

The most common ADRs seen in clinical studies (frequency >= 10% of patients) were pyrexia, headache, cough, nasopharyngitis, vomiting, arthralgia and limb injury.

Baxter's ADVATE gets FDA approval for prophylaxis of Hemophilia A in adults, children

The most common Grade greater than or equal to3 treatment-emergent adverse events were neutropenia, diarrhea, colitis, pneumonia, rash and pyrexia. These data build upon the previously reported positive DUO results and further support oral duvelisib monotherapy as an effective oral treatment option for patients with relapsed or refractory CLL/SLL.

Verastem says duvelisib achieves 73% ORR in extension study

It is characterized by fetid red-brown watery uterine discharge along with pyrexia (Drillich et al., 2001), reduced milk yield, dullness, inappetance or anorexia, elevated heart rate and apparent dehydration.

Bovine puerperal metritis and its management--a report of two cases

In part II, 40 to 50 patients on ACZ885 (80%) reported adverse events, mainly arthralgia, cough, pyrexia and nasopharyngitis against 35-50 (70%) placebo patients previously treated with ACZ885.

Novartis ACZ885 Phase III trial shows reduced steroid use in 45% of SJIA patients

The most frequent treatment-related adverse events were nausea, peripheral edema, headache, and pyrexia; 8% had infections and 3% had neutropenia deemed treatment-related.

AstraZeneca's Moxetumomab Pasudotox study meets primary endpoint

A three year old non-descript male dog was presented with the complaint of pyrexia, anorexia and vomiting since three days.